Hemodialysis patients with secondary hyperparathyroidism have higher rates of mortality, readmission, and reoperation than those with primary hyperparathyroidism, so parathyroidectomy is associated with higher costs, according to investigators.
In a study, CKD patients with vitamin D insufficiency had greater reductions in proteinuria severity after receiving low-dose calcitriol with RAAS blockade.
An Italian study of dialysis patients with secondary hyperparathyroidism found a 19% lower all-cause hospitalization rate for high vs low adherers to cinacalcet.
In a study of hemodialysis patients, similar proportions of thrice-weekly and once-daily cinacalcet users achieved PTH levels of less than 600 pg/mL within 6 months.
Maintenance hemodialysis patients with SHPT who switched from IV vitamin D analogs to oral calcitriol had similar serum levels of iPTH, calcium, and phosphate at 12 months as those who continued on the IV treatment.
